4D Molecular Therapeutics Inc (NASDAQ: FDMT) kicked off on Monday, up 8.20% from the previous trading day, before settling in for the closing price of $11.34. Over the past 52 weeks, FDMT has traded in a range of $2.23-$12.34.
A company in the Healthcare sector has dropped its sales by -9.89% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -23.51%. With a float of $41.39 million, this company’s outstanding shares have now reached $46.70 million.
4D Molecular Therapeutics Inc (FDMT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 11.38%, while institutional ownership is 81.91%. The most recent insider transaction that took place on Oct 24 ’25, was worth 32,136. In this transaction Chief Legal Officer of this company sold 2,678 shares at a rate of $12.00, taking the stock ownership to the 3,594 shares. Before that another transaction happened on Oct 24 ’25, when Company’s Officer proposed sale 1,816 for $10.00, making the entire transaction worth $18,160.
4D Molecular Therapeutics Inc (FDMT) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.79 earnings per share (EPS), lower than consensus estimate (set at -0.7) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.88 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -23.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.91% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Take a look at 4D Molecular Therapeutics Inc’s (FDMT) current performance indicators. Last quarter, stock had a quick ratio of 8.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19101.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.71, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -3.80 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.24 million. That was better than the volume of 0.85 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.36%.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 99.19%, which indicates a significant increase from 98.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.02 in the past 14 days, which was higher than the 0.51 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.12, while its 200-day Moving Average is $5.20. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $12.77. Second resistance stands at $13.27. The third major resistance level sits at $14.22. If the price goes on to break the first support level at $11.32, it is likely to go to the next support level at $10.37. Assuming the price breaks the second support level, the third support level stands at $9.87.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
The company with the Market Capitalisation of 573.04 million has total of 46,702K Shares Outstanding. Its annual sales at the moment are 40 K in contrast with the sum of -160,870 K annual income. Company’s last quarter sales were recorded 20 K and last quarter income was -54,660 K.
